Published on

Pharmacoidea Ltd. is a Hungarian biotech company specialized in drug discovery and functional food develeopment. Led by Tamas Letoha, MD, PhD, Pharmacoidea’s team is selected from forward thinking biologists, chemists and medical doctors whom are interested to solve important medical problems and translate basic science results rapidly into innovative threapeutics, incorporating high added value by rational drug design and food engineering.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. Bringing Novel Therapeutics to Everyday Life
  2. 2. Pharmacoidea Ltd. The Company: a biotech SME founded in 2006, Szeged, Hungary CEO: Tamas Letoha, MD, PhD Mission: To bring safe and innovative therapeutics against diseases with unmet medical needs• Team: selected from forward thinking scientists interested to translate basic science results rapidly into innovative therapeutics, incorporating high added value by rational drug design and food engineering• Laboratory: based in the Biological Research Center of the Hungarian Academy of Sciences (
  3. 3. Novel Drug Delivery TechnologiesIntracellular Targeting of Molecules(PCT/IB2007/052787):– A novel approach for targeting membrane impermeable drugs– New drug target against viral infections– 2008. June, Cardiff, UK – Cellular Delivery of Therapeutic Macromolecules, Drug Discovery Today Award– 2009. September, Montpellier, France 3th Conference of Intracellular Delivery of Therapeutic Molecules: From Bench to Bedside, Award of the French Innovation and Transfer Office– 2012. Innovative Medicines Innitiative: PharmacoIdea is part of the COMPACT Consortium in the topic of „Drug Delivery”
  4. 4. Molecular Carcinoma SurgerySelective elimination of breast & prostate cancer cells – Conditionally lethal stem cells equipped with a killer gene – Prostate cancer – 15% of cancers – 200 000 new patients in the US – Breast cancer – 2nd most frequent cancer – 502 000 death annually (1% of total deaths) – R&D project supported by the National Development Agency
  5. 5. Protein aggregation diseases– Degenerative diseases based on pathological aggregation of misfolded proteins • Alzheimers disease ( 10% prevalence at the age of 65 years and 50% at the age of 85 or above) • Parkinsons disease ( 0.37% of the whole population ) • Type II diabetes (150 million cases worldwide in 2002 ) • Age-related macular degeneration ( 2% of the population aged 50 and 30% of the population aged 75 years or more )– Common molecular pattern– Presently incurable, prevention is the only option– Aim: development of scientifically validated prophylactic agents
  6. 6. Protein aggregates (plaques) β-amyloid (Alzheimer) α-synuclein (Parkinson) amylin(Type II Diabetes) drusen (AMD)
  7. 7. Plaque depositionBrain → Alzheimer, ParkinsonPancreas → Type II DiabetesEye (retina) → AMD Plaque in the brain Plaque deposition -> neuronal death -> dementia
  8. 8. Plaque Busters High-throughput bioassays + transgenic animal models +in silico modeling and docking algorithms + structure-activity relationships a molecular library of new chemical entities – like thorough molecular lancets, plaque busters can specifically recognize and eliminate pathological protein aggregates/plaques (see figure below)Healthy brain Alzheimer brain Alzheimer brain + Plaque Busters
  9. 9. MentalFitol™ MentalFitol Molecular biology/pharmacology + bioinformatics + clinics A mix of health preserving botanical agents developed with state-of-the-art drug discovery approaches A syndergic blend of bioactive herbs and spices Compounds has been validated from bench to bedside clinical studies in Alzheimer’s (Disclaimer: MentalFitol™ food products are not intended to diagnose, treat, cure or prevent any disease.)
  10. 10. „Let food be thy medicine” Major change in consumer’s demands: optimal diet can prevent 25-70% of lifestyle-related diseases → awareness of the benefits of healthy eating Development of value-added functional food products – the global market of functional food industry will reach 176.7 billion USD in 2013 with a compound annual growth rate of 7.4% – developed with scientific tools of the 21st century, food products capable of specific elimination of causative targets of endemic diseases will conquer international food markets
  11. 11. MentalFitol™ food family Great variety from the internationally acknowledged Co’s of the PharmacoFood Cluster (~1 billion € turnover/year) Bakery, pastry, dairy, meat products, matzo, pasta, pizza, sauces, vega food etc. MentalFitol™ functional food products offer the pleasure of eating while delivering scientifically validated health- preserving bioactive compounds, thus contributing to the improvement of life quality for large costumer populations ,,, (Disclaimer: MentalFitol™ food products are not intended to diagnose, treat, cure or prevent any disease.)
  12. 12. ”One Bite Fits All!”sausages ready-made meat matzo pasta
  13. 13. ContactTamás Letoha, MD, PhD Chief Executive Officer (CEO)Address: Körös sor 50, 6753 Szeged, HungaryPhone: +36(30)257-7393E-mail: tamas.letoha@pharmacoidea.euHomepage: